(Q53099028)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24292520%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24292520%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

0 references

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24292520%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

N Jaekel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24292520%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

G Behre

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24292520%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

A Behning

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24292520%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

C Wickenhauser

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24292520%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

T Lange

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24292520%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

D Niederwieser

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24292520%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

language of work or name

English

0 references

publication date

2 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24292520%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24292520%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24292520%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24292520%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

179-184

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24292520%20AND%20SRC:MED&resulttype=core&format=json

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.173

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.173

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.173

Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.173

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.173

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.173

JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.173

Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.173

Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.173

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.173

Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.173

Outcome of transplantation for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.173

Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.173

The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.173

JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.173

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.173

Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.173

Inheritance of the chronic myeloproliferative neoplasms. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.173

Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.

21 January 2018

1 reference

12 December 2020

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

1 reference

12 December 2020

Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia

1 reference

12 December 2020

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

12 December 2020

A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis

1 reference

12 December 2020

Graft-versus-host disease

1 reference

12 December 2020

Identifiers

DOI

10.1038/BMT.2013.173

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24292520%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference